How do stelara's secondary patents impact biosimilar entry?

Stelara is ustekinumab (Janssen) and is a biologic. “Secondary patents” usually refers to later-expiring patent estate pieces (often covering specific formulations, dosing regimens, manufacturing changes, methods of use, or additional combinations) that can delay a biosimilar’s approval and/or launch even after the “primary” (earliest) exclusivity ends.

Here’s how they typically impact biosimilar entry:

1) They can block (or delay) approval/litigation outcomes

In the US, a biosimilar applicant may be able to file under §351(k), but litigation risk and the patent listing process still matter. If secondary patents are listed in the Orange Book–style biosimilar patent lists (via FDA “patent dance” procedures), the sponsor often has to address them through one of the statutory notice pathways (e.g., non-infringement, invalidity, or expiration).

Practical effect: even if the biosimilar is scientifically ready, entry may be delayed if courts find infringement or if the applicant elects/negotiates around the patents.

2) “Patent thickets” make it harder to launch quickly

Stelara likely has multiple layers of patents (not just one). Secondary patents can create a thicket, meaning there may be several patents that—on the face of the claims—could cover:

• the approved dosing schedule (e.g., loading then maintenance)
• specific indications/populations
• aspects of formulation or device/container
• certain manufacturing processes or product attributes

If any one or more of these remain enforceable and asserted, the biosimilar may be forced to delay launch to avoid infringement exposure.

3) They can delay commercial “at-risk” launch or settlement terms

Even when a biosimilar is FDA-approved, the innovator can sue for infringement. Companies sometimes launch “at risk” or wait depending on:

• strength of the patent(s)
• likelihood of injunctions
• settlement dynamics

Secondary patents often become leverage points for settlement timing, producing a slower path to market entry than the earliest expiration date might suggest.

4) They can restrict “skinny label” vs “totality” strategies

If secondary patents are tied to a particular indication or regimen, a biosimilar might attempt a label restriction (“carve-out” / “skinny label”) to avoid infringement. But this only works if the remaining claim scope aligns with the biosimilar’s intended labeling and the legal strategy is successful.

5) International differences can change the impact

The exact mechanics depend on jurisdiction:

• US: Orange Book/Biosimilar patent listing + litigation/injunction dynamics
• EU/UK: patent enforcement and timing depends more on national litigation and patent courts
• Other markets: may rely more heavily on regulatory exclusivities or local patent enforcement

So secondary patents can matter everywhere, but how they delay entry differs by country.

If you want, I can be more specific

To explain Stelara’s impact precisely, I’d need one of the following:

1. Country (US vs EU vs UK, etc.)
2. Whether you mean ustekinumab biosimilars for psoriasis, Crohn’s, ulcerative colitis (or all)
3. The specific “secondary patent” numbers or claim types you’re referring to (e.g., dosing/formulation/method-of-treatment)

If you tell me the jurisdiction and indication, I can map out the typical delay mechanisms and what kinds of secondary patents most often affect biosimilar entry.